Buy & Sell Allakos Inc (ALLK) – Allakos Inc Price Today
Key Stats
- $29.74MMarket Cap
- HealthSector
- -3M Drawdown
- -$46.92MEnterprise Value
- -Dividend Yield
- 37 daysTypical Hold Time
Allakos Inc (ALLK) is currently valued at a market capitalization of $29.74M, with an enterprise value of -$46.92M. Over the past 52 weeks, Allakos Inc has traded between a low of $0.22 and a high of $1.5, highlighting its annual price range. On average, investors hold Allakos Inc for approximately 37 days, indicating typical investor behavior on the platform.
About Allakos Inc
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Most Recent News
SaintQuant launches free AI trading bot with $7 bonus to automate investing for all users.
SaintQuant has introduced a free AI-powered trading bot platform that offers new users a $7 real cash bonus upon registration. The platform uses advanced quantum AI to provide continuous, automated trading with institutional-grade risk management, re...
US stock futures rise after Iran conflict dubbed a 'love tap' by Trump; investors await April jobs data.
US stock futures increased following a minor military exchange near the Strait of Hormuz between US and Iranian forces, which former President Donald Trump described as a 'love tap.' Despite geopolitical tensions, markets focus on strong tech earning...
SoftBank cuts OpenAI margin loan target from $10B to $6B amid lender concerns.
SoftBank is reportedly reducing its planned margin loan backed by its OpenAI stake from $10 billion to as low as $6 billion due to lender caution over OpenAI's valuation. The loan, intended to support SoftBank's continued AI investments, faces scruti...
